Healthcare Global Enterprises Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Volume-led growth with margin lift: Revenue grew 12% YoY, two-thirds from volume, while EBITDA margin reached 19% on better service/payer mix and operating leverage.
• Emerging centers are turning the corner: Kolkata turned EBITDA positive, South Mumbai losses shrank significantly and breakeven is expected mid-year, removing a key drag on consolidated profitability.
• Capacity expansion is accelerating: After a consolidation phase, HCG is deploying 500 beds within three years and 800-900 over five, headlined by a new 200-bed Ahmedabad facility opening next month.
• Doctor retention is a structural moat: Top doctor attrition is under 5%, supported by an institutional brand, internal training programs, and academic research that make HCG a destination rather than a stepping stone.
• What to watch next quarter: The pace of the Ahmedabad ramp-up in its new facility, whether South Mumbai hits its mid-year breakeven target, and any concrete M&A announcements from the assets under evaluation.

Volume-Led Growth Model

• Volume is the primary engine: Two-thirds of recent revenue growth came from volume, driven by deployed bed capacity, linear accelerator and OT capacity, added clinicians, and strengthened go-to-market efforts. Management expects this trend to continue.
• Oncology growth is not bed-dependent: The average length of stay is decreasing as oncology shifts outpatient. The hub-and-spoke model with clinics and infusion centers contributes revenue without beds, so footfall is a better growth metric than bed strength alone.
• Peer comparison explained: Multi-specialty peers focusing on oncology show higher YoY growth due to a smaller base and higher concentration in specific markets. HCG's larger base and deliberate focus on volume-led rather than realization-led growth explains the difference.
• Consolidation phase is ending: HCG has been in a consolidation phase while peers expanded. It is now deploying additional capacity in key centers like Ahmedabad and Cuttack, which should accelerate growth.

Dr. B.S. Ajaikumar: "In oncology, you should never focus only on beds. As we go forward, oncology is more outpatient, more time-related treatment and also we should look at the growth in oncology, not clearly just measured by the beds alone."

Margin Trajectory & Profitability Levers

• Q4 margin of 19% explained: The improvement came from a better service mix, better payer mix, and operating leverage from strong revenue growth. First-half margins were subdued due to investment in clinical bandwidth and downtime while transitioning linear accelerators.
• Emerging center drag is reversing: Kolkata turned EBITDA positive in Q3 and Q4. South Mumbai is reducing losses and expected to break even mid-year. As these two former drags contribute positively, the emerging center bucket will move in the right direction throughout the year.
• South Mumbai is a premium asset: It is the only Western India hospital with CyberKnife and Tomotherapy under one roof, staffed with high-pedigree clinical talent including an ex-Nottingham breast oncologist and a Memorial Sloan Kettering-trained breast surgeon. International patients contribute 30-35% of revenue. Losses have significantly reduced this year.
• Borivali is a well-performing template: The asset follows strong unit economics with 20%-plus growth and mid-20% EBITDA margin, even after adding one LINAC, a surgical robot, and vertical surgical specialization. Spare capacity remains on all modalities.
• Capacity utilization dipped on proactive expansion: Utilization fell from 65% to 61% due to the incorporation of four new linear accelerators, a deliberate investment ahead of demand.

Raj Gore: "EBITDA margin that we see in Q4 is on account of better service mix and a payer mix and operating leverage due to a strong revenue growth. We expect that to continue going forward."

Capacity Expansion Pipeline

• Ahmedabad is the near-term catalyst: The existing sub-100-bed hospital faced capacity constraints in ICU beds and OTs (only 5 OTs) despite being a surgery-dominant center with 20-plus surgical oncologists. The new 200-bed facility doubles OT capacity to 10 with headroom for more, and the transition happens next month.
• Bangalore gets two new hospitals: Two hospitals totaling 125 beds in North Bangalore and Whitefield are slated to be operational in the next 12-15 months. Combined with about 20 beds and two OTs added in the center of excellence last year, Bangalore has enough bed capacity to grow for the next five years.
• Five-year bed visibility is 800-900 beds: Within three years, HCG plans to deploy 500 beds. After three years, another 200-300 beds. This includes Cuttack (adding 60-70 beds, large expansion likely next financial year) and Vizag (adding 25-30 beds next year, another 25-30 in two to three years).
• Brownfield first, then new markets: The first priority is investing in the current 18-19 locations. Management sees enough headroom in existing hospitals to continue growing for the next five years across all capacity parameters.
• Daycare centers extend the hub-and-spoke: A couple more daycare centers will be added in Bangalore in the next 12-18 months, contributing revenue without the bed-intensity of inpatient facilities.

Raj Gore: "In all capacity parameters, we have enough headroom in our current hospitals to continue to grow for the next five years."

Multi-Specialty Hospital Strategy

• Oncology is becoming dominant in multi-specialty assets: Bhavnagar added one LINAC and is looking at adding another. Rajkot started surgical and medical oncology last year and is building a bunker for comprehensive cancer care. Suchirayu, a strong referral center for North Karnataka, is building a bunker for a LINAC and PET scan, after which oncology will become the dominant specialty.
• Ahmedabad HMS will remain multi-specialty: Unlike the other assets, the HMS facility has no space for oncology and will continue as a multi-specialty hospital.
• The playbook is replicable: The strategy of adding oncology capabilities to multi-specialty hospitals in underserved markets creates referral-dominant cancer care hubs without the cost of Greenfield builds.

Inorganic Growth & Capital Allocation

• HCG sees itself as a consolidator: Management stated it is uniquely poised for this role and is evaluating several key assets. The preference is for targets in existing or adjacent markets, though it will be opportunistic for a good acquisition in a newer state.
• Investment will be proportionate to asset size: Management declined to comment on the size of potential acquisitions, stating it is difficult to specify until something is concrete.
• Funding mix is internal accruals plus debt: HCG is comfortable with current debt covenants and will fund inorganic growth through internal accruals and external debt, while remaining mindful of debt levels with internal guidance.
• Effective tax rate will normalize: The rate is currently elevated at 39% because HCG does not take tax credit on ₹47 crore of losses from loss-making entities. As those entities become profitable, the effective rate will reduce.

Clinical & Digital Differentiation

• Technology investments are a moat: HCG plans to introduce MR LINAC radiation therapy in Bangalore, integrating magnetic imaging with a linear accelerator. Robotics additions will transform precision medicine in the genomics era.
• Institutional Research Committee is unique: HCG established a committee to fund investigator-initiated trials, described as one-of-a-kind in the Indian private health sector, reinforcing its academic and research credentials.
• Clinical milestones demonstrate depth: Record numbers of minimal access head and neck surgeries in Bangalore, Neuro SAFE nerve-saving prostatectomy, robotic-assisted breast axillo thyroidectomy (a Mumbai first), and significant numbers of 3D-planned large tumor resections were achieved in the quarter.
• Digital patient engagement is scaling: The HCG Care Smart App, launched for patient access to treatment options and medical records, already has over 56,000 outpatients and 300-plus doctors active. Digital revenue will continue to be an important growth driver.
• Doctor retention is structurally protected: Top doctor attrition is under 5%, driven by empowerment, academic and research opportunities, internal training programs including fellowship and residency, and an institutional brand that makes HCG a destination.

Dr. B.S. Ajaikumar: "Doctors who want to even sometimes leave… because we have an internal training mechanism and because we brand HCG more than doctor and we collaborate with doctors and work, we don't see that as a foreseeable issue at all."

Guidance & Commitments

Key Metrics